Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

By S. Gilman, M. Koller, R. Black, L. Jenkins, S. Griffith, Nick C Fox, L. Eisner, L. Kirby, M. B. Rovira, F. Forette and 1 more. Neurology, 2005

1,333 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/de546ccaf358945a961e6be468b12b11347ac9c4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pathology and Forensic Medicine

John Hardy

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide (2007, background): “A later report, which included all of the vaccine-trial subjects, could not confirm an overall benefit on such general cognitive test”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “and data from the interrupted Phase IIa AN1792 tria”
Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, background): “However, most of clinical trials targeting at Ab are not demonstrated to show more significance efficacy than control placebo, though some of them effectively clear Ab deposits in AD brain (Gravitz, 2011; Holmes et al., 2008; Gilman et al., 2005; Orgogozo et al., 2003).”
Therapeutics of Alzheimer's disease: Past, present and future. (2014, background): “Later it became clear that about 60% of patients responded with antibody production and neurophysiological test battery indicated favorable performance in them (Gilman et al., 2005).”
Current and future treatments for Alzheimer’s disease (2013, background): “In a small subset of patients, CSF tau levels were decreased in antibody responders but Aβ levels were unchanged [Gilman et al. 2005].”
Alzheimer's disease. (2011, background): “…some subjects were followed and showed limited evidence of a biological effect, namely fewer declines than placebo-treated subjects on certain memory tests that correlated with their residual Ab antibody titers, plus a lowering of CSF tau levels in a small subset of recipients (Gilman et al. 2005).”
The amyloid hypothesis of Alzheimer's disease at 25 years (2016, background): “…longer at the forefront but not forgotten AD immunotherapy in man began with an active vaccine trial (using AN-1792, a synthetic Ab1–42 peptide) that was terminated after 2–3 doses due to the occurrence of a T-cell mediated meningeal inflammation in 6% of the Phase 2 patients (Gilman et al, 2005).”